Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Call to prioritise nanomedicine:

This article was originally published in Clinica

Executive Summary

Nanomedicine is a valuable new technology for diagnostics and should have a higher profile in medicine, according to influential medical journal The Lancet. The statement in its August 30 2003 issue follows a review of nanoscience by the US National Institutes of Health (NIH), which highlighted disease diagnosis and treatment as key areas in which the discipline could help mankind. According to NIH, nanostructures (defined as between 1-100nm in size) offer "novel means for body or organ imaging. Nanotweezers and surgical tools only a few nanometers thick are already in development. Nanoprobes may be able to add diagnostic specificity to biopsy studies."

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT063445

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel